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ABSTRACT
The effects of somatostatin (SS-14 and/or SS-28) and of the three
octapeptide SS-analogs that are available for clinical use (octreotide,
BIM-23014 and RC-160) on hormone release by primary cultures of
15 clinically nonfunctioning pituitary adenomas (NFA), 7 prolacti-
nomas, and 2 insulinomas were investigated. In the pituitary ade-
noma cultures, a comparison was made with the effects of the dopa-
mine (DA) agonists bromocriptine and/or quinagolide. In 5 NFAs, 2
prolactinomas and 1 insulinoma somatostatin receptor (subtype) ex-
pression was determined by ligand binding studies and by in situ
hybridization to detect sst1, sst2, and sst3 messenger RNAs (mRNAs).
Four NFA cultures did not secrete detectable amounts of a-subunit,
FSH, and/or LH. In the other cultures, hormone and/or subunit re-
lease was inhibited by DA-agonists (10 nM) in 9 of 11, by SS (10 nM)
in 7 of 11, and by octapeptide SS-analogs (10 nM) in 3 of 10 cultures.
In three NFA cultures, hormone release was sensitive to SS but not
to SS-analogs. In all cultures, except for one, DA-agonists were the
most effective in inhibiting hormone release. In the prolactinoma
cultures, PRL release was inhibited by DA-agonists (10 nM) in 7 of 7,
by SS in 4 of 4, and by octapeptide SS-analogs in 3 of 7 cultures. A
dissociation between the effects of SS and SS-analogs was found in 3
cases. In the cultures sensitive to both bromocriptine and SS-28,
bromocriptine was the most potent compound in 2 out of 4 cultures.
In the 2 other cultures, both compounds were equally effective. In 2
insulinoma cultures, insulin release was inhibited by SS, and by
octapeptide SS-analogs in only one. The presence or absence of an
inhibitory effect by octreotide was in all cases in parallel with the
presence or absence of the inhibitory effect by BIM-23014 and RC-160.
Autoradiographic studies using [125I-Tyr0]SS28 showed specific
binding in 4 of 5 NFAs, 1 of 2 prolactinomas, and 1 of 1 insulinoma.
Specific [125I-Tyr3]octreotide binding was found in 2 of 5 NFAs, in 1
of 2 prolactinomas, and in the insulinoma. Two NFAs showed binding
of SS28, but not of the sst2,5 specific ligand octreotide. The tumors
showed variable sst1 and/or sst3 mRNA expression, whereas no sst2
expression was found.
In conclusion, a dissociation between the inhibitory effects of SS on
the one hand and of the octapeptide SS-analogs octreotide, BIM-23014
and RC-160 on the other hand, is observed in a small subgroup of
NFAs, prolactinomas, and insulinomas, suggesting that novel sst
subtype specific SS-analogs might be of benefit in the treatment of
selected patients with somatostatin receptor positive secreting tu-
mors not responding to octapeptide SS-analogs. However, in the ma-
jority of NFAs and prolactinomas, DA-agonists were equally or more
effective than SS in the suppression of tumoral secretion products.
(J Clin Endocrinol Metab 82: 3011–3018, 1997)
RECENTLY, five distinct somatostatin receptor (sst) sub-types have been cloned and characterized (1–4). All sst
subtypes bind native somatostatin (SS) with high affinity,
whereas differences have been found between sst1–5 in the
binding of structural analogs of SS. Octreotide, which is the
most widely used SS-analog, successfully controls hormonal
hypersecretion in a majority of patients with neuroendocrine
tumors (5). This SS-analog binds with a high and relative
high affinity to sst2 and sst5, respectively, with low affinity
to sst3, and has no affinity to sst1 and sst4. Two other SS-
analogs, BIM-23014 (lanreotide) and RC-160 (vapreotide),
show a binding profile comparable to that of octreotide (1–4).
From several studies using different techniques, it has
become clear now that the majority of the human sst positive
tumors express multiple sst subtypes. While the majority of
the neuroendocrine tumors carry sst with a high affinity for
native SS as well as for the octapeptide SS-analog octreotide,
small subgroups of tumors have been described with high
affinity binding sites for SS but not for octreotide (6). Among
these tumors are certain insulinomas, carcinoids, medullary
thyroid carcinomas, ovarian tumors, and pituitary adeno-
mas. Absence of the sst2 subtype has been associated with an
absent hormonal response to treatment with octreotide, sug-
gesting that sst2 is involved in the antihormonal actions of
SS-analogs like octreotide (7, 8), whereas sst2 seems to be
involved in the inhibition of GH secretion in rats (9). So far,
however, the functional role of the other sst subtypes, is
unclear.
In a previous study, we have compared the effects of the
three SS-analogs (octreotide, BIM-23014, and RC-160) on hor-
mone release by pituitary GH-adenomas and a gastrinoma in
vitro (10). In this study, we found that GH-adenomas with an
absent hormonal response to octreotide were unresponsive
to BIM-23014 and RC-160 as well. Still, two major questions
remain. First, are there differences between the inhibitory
effects of the above mentioned three clinically applicable
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SS-analogs in other types of secreting tumors? Second, is
there evidence for a functional role of sst subtypes other than
those with a high affinity for octapeptide SS-analogs?
In order to further investigate these questions, we have
compared in the present study the effects octreotide, BIM-
23014, and RC-160 with that of native SS on hormone release
by the cultured cells prepared from 15 NFAs, 7 prolactino-
mas, and 2 insulinomas. In the pituitary adenoma cultures,
a comparison with the effects of dopamine agonists was also
made. Whereas several authors have described the effects of
either SS or octreotide on NFAs (11, 12), a direct comparison
between SS and SS-analogs on hormone release by NFAs has
not been made yet.
Materials and Methods
Patients
Pituitary tumor samples were obtained by transsphenoidal operation
from 18 patients with NFAs and from 7 patients with prolactinomas, as
described previously (13). Tumor samples of 2 insulinomas were ob-
tained within 30 min after surgical removal of the tumors. Diagnosis was
made on the basis of clinical and biochemical characteristics of the
patients, in combination with (immuno)histochemistry of the tumor
samples. All patients gave their informed consent for the use of tumor
material for research purposes. When sufficient adenoma tissue was
obtained, pieces were frozen on dry ice and stored at 280 C.
Cell dispersion and cell culture.
Fifteen out of 18 NFAs and 7 prolactinomas were used for the cell
culture studies. Single cell suspensions of the pituitary adenoma tissues
were prepared by enzymatic dissociation with dispase as described in
detail previously (13). Tumor tissue from the insulinoma patients was
dissociated as described (14).
Short-term incubation of monolayer cultures. the dissociated cells were
plated in 48-well plates (Costar, Cambridge, MA) at a density of 105
(prolactinomas and insulinomas) or 2 3 105 (NFAs) cells per well per 1
ml culture medium. After 3–4 days, the medium was changed, and 72-h
incubations without or with SS, SS-analogs, or DA-agonists were started.
At the end of the incubation, the medium was removed and centrifuged
for 5 min at 600 3 g. The supernatant was collected and stored at 220
C until analysis.
Long-term incubation studies in Transwells (15). The isolated tumor cells
were plated in Transwell-COL membranes (Costar, Badhoevedorp, The
Netherlands) at a density of 105 (prolactinomas and insulinomas) or 2 3
105 (NFAs) cells per well. The transwells were then placed into multiwell
plates (24-well, Costar) containing 1 ml culture medium. After 24 h, the
transwells were transferred to wells containing fresh medium (without
or with test substances). Every 3–4 days, the cells were placed into fresh
medium and the incubation media were collected and stored at 220 C
until determination of hormone concentrations.
In all experiments SS (SS-14 and/or SS-28), octapeptide SS-analogs
(octreotide, BIM-23014, RC-160) and DA-agonists (bromocriptine
and/or quinagolide) were used at a concentration of 10 nm. The cells
were cultured at 37 C in a CO2-incubator. The culture medium consisted
of MEM D-valine with Earle’s salts supplemented with nonessential
amino acids, sodium pyruvate (1 mmol/L), 10% FCS, penicillin (1 3 105
U/L), fungizone (0.5 mg/L), l-glutamine (2 mmol/L), and sodium bi-
carbonate (2.2 g/L). Unfortunately, generally not enough tumor material
was obtained to test each tumor on its responsiveness to all of the above
indicated drugs.
Hormone determinations
Human PRL, LH, and FSH concentrations in the media were deter-
mined by immunoradiometric assays (MedGenix Diagnostics, Fleurus,
Belgium) as described previously (13, 15). Glycoprotein a-subunit con-
centrations were determined by an immunoradiometric assay from Im-
munotech S. A. (Marseille, France). Insulin concentrations were deter-
mined by a double antibody RIA as described (14). Dilution of PRL, LH,
FSH, a-subunit and insulin in the media was in parallel to the respective
standards supplied with the kits.
Test substances
Somatostatin-14 (SS-14) was obtained from Sigma (St. Louis, MO).
BIM-23014 (lanreotide) and somatostatin-28 (SS-28) were obtained from
Bachem (Hannover, Germany). RC-160 (vapreotide) was obtained from
Peninsula (Belmont, CA). Octreotide, bromocriptine and quinagolide
(CV205–502) were obtained from Sandoz Pharma (Basle, Switzerland).
Receptor autoradiography
Receptor autoradiography was carried out as described by Reubi et
al., (16). Ten-micrometer sections were mounted onto precleaned gelatin
coated microscope slides, and stored at 280 C. Adjacent sections were
used for in situ hybridization and processed further as described below.
To wash out endogenous somatostatin, the sections were preincubated
at room temperature for 10 minutes in 170 mm Tris-HCl, pH 7.4. There-
after, the sections were incubated for 60 minutes at room temperature
in 170 mm Tris-HCl, pH 7.4, 5 mm MgCl2, 1% BSA, 40 mg/ml bacitracin
in the presence of [125I-Tyr3]-octreotide (about 80–160 pmol/L) or [125I-
Tyr0]SS28 (final concentration 80–160 pmol/L; ANAWA Laboratories,
Wangen, Switzerland). Nonspecific binding was determined in a se-
quential section in the presence of excess unlabeled Tyr3-octreotide (1
mm) or SS-28 (1 mm). The incubated sections were washed twice for 5 min
in incubation buffer containing 0.25% BSA and once in incubation buffer
without BSA. After a short wash with distilled water to remove salt, the
sections were air dried and exposed to Kodak X-OMAT AR or Hyper-
film-3H (Amersham) for 3–7 days in x-ray cassettes. Histology was
performed on hematoxylin-azophloxine stained sequential cryosections.
In situ hybridization histochemistry of sst1, sst2, and sst3
mRNA
The protocol and oligonucleotides used for in situ hybridization were
the same as described by Reubi et al. (17). Forty-eight base pair oligo-
nucleotides complementary to the bases coding for amino acids 2–17 of
the hsst1 mRNA sequence, 237–252 of the hsst2 sequence, and 366–381
of the hsst3 sequence (17) were synthesized and purified over a Phar-
macia NAP-10 column by Pharmacia Biotech (Roosendaal, The
Netherlands). 39-end labeling by using [a-32P]dATP (3000 Ci/mmol;
Du Pont NEN , Boston, MA) was performed as described previously (18).
Specificity of hybridization signal obtained with the above oligonucle-
otide probes was established previously (17). In our study, sequential
cryostat sections of the tumors (see above) were incubated in duplicate
with 32P-labeled oligonucleotide probes without or with a 20-fold excess
of unlabeled oligonucleotide to demonstrate specificity of the hybrid-
ization signal obtained. A tumor was considered positive for the re-
spective mRNA when the hybridization signal obtained in a control
section was displaced by a 20-fold excess of unlabeled oligonucleotide
by more than 50%. The hybridization signals obtained were analyzed
densitometrically.
Statistical analysis of the data
All data on hormone release are expressed in mean 6 se, n 5 4 wells
per treatment group. All data were analyzed by ANOVA to determine
overall differences between treatment groups. When significant differ-
ences were found by ANOVA, a comparison between treatment groups
was made using the Newman-Keuls test.
Results
Clinically nonfunctioning pituitary adenomas
Table 1 shows basal release of a-subunit, FSH, and LH by
cultured cells of NFAs 1–6. Five out of 6 NFA cultures se-
creted detectable amounts of a-subunit in vitro, 5 out of 6
secreted FSH, whereas only 2 of 6 (no. 1 and 2) secreted LH.
Hormone release was not inhibited by SS-28 (10 nm), oct-
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reotide (10 nm), RC-160 (10 nm), or BIM-23014 (10 nm) in a
72-h exposure of the cells in 3 out of 6 cultures (nos. 2, 4, and
5, data not shown). In culture no. 5, however, the DA-agonist
quinagolide (10 nm) significantly inhibited a-subunit and
FSH release by 48 and 30%, respectively (P , 0.01 vs. control
cells, data not shown). The effect of SS-28, SS-analogs, and
quinagolide (all used at a concentration of 10 nm) on a-sub-
unit or FSH release by NFA cultures 1, 3, and 6 is shown in
Fig. 1. Quinagolide significantly inhibited a-subunit or FSH
release during a 72-h exposure in all cultures (P , 0.01 vs.
control cells), whereas in cultures no. 1 and 3 both SS-28 and
octreotide significantly inhibited hormone release (P , 0.01
vs. control cells). In culture no. 3, SS-28, octreotide, RC-160,
and BIM-23014 were equally effective. However, in culture
no. 6, which was sensitive to the inhibitory effect of SS-28,
none of the three octapeptide SS-analogs were effective in
inhibiting FSH release. In NFA culture no. 1, the response of
FSH and LH release was comparable with that of a-subunit
release, whereas in culture no. 3, a-subunit release was not
inhibited (data not shown).
In nine NFA cultures (nos. 7–15), the effects of bromocrip-
tine (10 nm), SS-28 (10 nm), and the three SS-analogs (10 nm)
were investigated during prolonged exposure in Transwell
tissue culture inserts (15). Four of these cultures (nos. 12–15)
did not secrete detectable amounts of LH, FSH, or a-subunit
(data not shown). Figure 2 shows the effects of the above-
mentioned drugs on a-subunit release by cultured cells from
NFA no. 7 and no. 10. In the cells of patient 7, a-subunit
release was progressively inhibited to the same extent by
SS-28 and the three SS-analogs. The degree of inhibition after
2 weeks of exposure in vitro was comparable to that of bro-
mocriptine. In NFA culture, no. 10 bromocriptine and SS-28
also increasingly inhibited a-subunit release, although bro-
mocriptine was most effective. After drug withdrawal on day
14, these inhibitory effects recovered, suggesting that the
increasing inhibitory actions of bromocriptine, SS-28 and
SS-analogs, represented inhibition of hormone release and or
production and not inhibition of cell proliferation. Table 2
shows the effects of bromocriptine, SS-28, and SS-analogs on
a-subunit-, FSH and/or LH release by NFAs no. 7–11, at day
14 of incubation. In all NFA cultures (7–11) bromocriptine (10
nm) significantly inhibited hormone release. SS-28 signifi-
cantly inhibited hormone release in cultures 7, 9, 10, and 11.
Octreotide, BIM-23014, and RC-160 significantly inhibited
hormone release in culture no. 7.
Overall, hormone release was sensitive to DA-agonists in
9 out of 11, to SS-28 in 7 out of 11, and to SS-analogs in 3 out
of 10 cultures. In three cases (nos. 6, 9, and 11) hormone
release was sensitive to SS, but not to SS-analogs. In all
cultures, except for one (no. 7), bromocriptine was the most
effective compound.
Prolactinomas
Quinagolide (10 nm) significantly inhibited PRL release
during a 72-h incubation in three prolactinoma cultures (nos.
1, 2, and 3) by 25, 33, and 50% respectively (data not shown).
In these three cultures, octreotide (10 nm) did not signifi-
cantly inhibit PRL release. At the same time, 10 nm RC-160
(in culture nos. 2 and 3) or 10 nm BIM-23014 (in culture no.
3) were also ineffective (data not shown).
In 4 prolactinoma cultures (nos. 4–7), the effects of SS-28,
octreotide, RC-160, BIM-23014, and bromocriptine (all at a
concentration of 10 nm) were studied during prolonged in-
cubation of the cells in Transwells. Figure 3 shows that PRL
release by the cells of adenoma no. 4 was slightly sensitive
to octreotide (statistically significant inhibition of PRL re-
lease at days 3, 10, and 14) but responded very well to SS-28
and bromocriptine (90 and 84% inhibition, respectively, day
14 of culture). In addition, we found that PRL release by the
cells of patient 5 was also increasingly inhibited by bro-
mocriptine and SS-28 (by 40 and 40%, respectively, day 14 of
culture; P , 0.01 vs. control cells), in contrast to the slight
(approximately 17%, day 14 of culture), but significant in-
hibition by the three SS analogs. Comparable to the NFA
cultures, drug withdrawal on day 14 in culture no. 5, led to
a recovery of PRL release. It is also important to note that the
maximal inhibition of PRL release by both SS-28 and bro-
mocriptine was considerably less in the culture of adenoma
no. 5 in comparison with culture no. 4. Patient no. 5 had
become insensitive to DA-agonist therapy, whereas patient
no. 4 was operated because of intolerance to DA-agonist
therapy. Table 3 shows the effects of the above compounds
on PRL release by culture nos. 6 and 7, at day 14 of incu-
bation. PRL release by adenoma cells from patients no. 6 and
7 (operated because of intolerance to DA-agonist therapy)
was significantly inhibited by bromocriptine, and slightly by
SS-28. Octreotide significantly inhibited PRL release in cul-
ture no. 6 only. The cells of patient 7 were unresponsive to
octreotide, BIM-23014, and RC-160.
Overall, hormone release was sensitive to DA-agonists in
all 7 prolactinoma cultures, to SS-28 4 of 4, and to octreotide
in 3 of 7. In 2 cultures (nos. 4 and 5) hormone release was
significantly inhibited by SS-28 and only slightly by oct-
reotide, BIM-23014, and RC-160. In those cultures sensitive
to both bromocriptine and SS-28, bromocriptine was the most
potent compound in 2 out of 4 cultures (nos. 6 and 7). In the
two other cultures, both compounds were equally effective.
Insulinomas
Table 4 shows the effect of SS-14, SS-28, and octreotide and
RC-160 (72 h incubation) on insulin release by cultured cells
of insulinoma no. 1. Both SS-14 (10 nm) and SS-28 (10 nm)
TABLE 1. Characteristics of hormone release in vitro by clinically
nonfunctioning pituitary adenomas (NFA)





NFA 1 6.1 6 0.1 18.4 6 1.7 1.3 6 0.1
NFA 2 5.3 6 0.5 16.1 6 0.6 2.0 6 0.1
NFA 3 0.5 6 0.0 4.6 6 0.2 Not detectable
NFA 4 2.6 6 0.2 Not detectable Not detectable
NFA 5 4.6 6 0.3 77.5 6 2.8 Not detectable
NFA 6 Not detectable 10.2 6 1.0 Not detectable
200,000 cells per well were plated in 24-well multiwell plates in 1
ml of MEM-Dval 1 10% FCS. On day 4 of the culture, the medium was
changed and a 72-h incubation was performed in quadruplicate.
a-Subunit (a-SU), FSH, and LH concentrations in the media were
determined as described in the Materials and Methods section. No
detectable amounts of GH, PRL, and ACTH were found in the media.
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significantly inhibited insulin release by 29 and 32%, respec-
tively (P , 0.01 vs. control). Octreotide (10 nm) and RC-160
(10 nm) were ineffective, however.
Cells of insulinoma no. 2 were cultured in Transwells in
the absence or presence of SS-14, SS-28, and SS-analogs.
Figure 4 shows that SS-14, SS-28, and the SS-analogs oct-
reotide, BIM-23014, and RC-160 progressively inhibited in-
sulin release to the same extent.
Somatostatin receptor subtype expression
Table 5 shows the results of the autoradiographic and in
situ hybridization experiments. It should be mentioned that
not sufficient material was obtained from each adenoma to
perform both the receptor and cell culture studies.
[125I-Tyr0]SS-28 binding was found in 4 out of 5 NFAs, in
1 out of 2 prolactinomas, and in insulinoma no. 2. Binding
of the sst2- and sst5- subtype selective ligand [
125I-
Tyr3]octreotide was parallel in all cases except for 2 NFAs
(nos. 9 and 18), which showed no binding of [125I-
Tyr3]octreotide. In the majority of the NFAs and prolactino-
mas, receptor density was low. The two NFAs that showed
binding of [125I-Tyr3]octreotide did not express the sst2 sub-
type, however. In addition, no sst2 mRNA expression was
found in the other NFAs and prolactinomas. One pheochro-
mocytoma and one carcinoid, which were already known to
express sst2 mRNA, were included as a positive controls for
sst2 mRNA expression (Table 5). One NFA (no. 11), which
showed binding of both radioligands, did not express sst1,
sst2, or sst3 mRNA. Two other adenomas (NFA no. 17 and
prolactinoma no. 6) showed sst3 expression, whereas no li-
gand binding was detected, possibly due to low levels of
expression of the receptor protein. Furthermore, the expres-
sion of sst1 and sst3 was variable. Insulinoma no. 2, which had
a high density of receptors, expressed sst1 and sst3 mRNA
only (Fig. 5).
Discussion
Experimental and human tumors of different cellular or-
igin express multiple sst subtypes. By various methods in-
cluding RT-PCR, RNAse-protection, and in situ hybridiza-
tion, it has been demonstrated that sst1, sst2, sst3, sst4, and sst5
mRNA can be expressed in different human pituitary ade-
nomas and insulinomas at the same time (7, 8, 19–21). The
expression of multiple sst subtypes in tumors makes it dif-
ficult to establish their functional role in mediating antihor-
monal and/or antiproliferative effects. A subgroup of neu-
roendocrine tumors, including pituitary adenomas and
insulinomas, express ssts with high affinity binding for SS-28
but not for octreotide (6). In the present study, we have
investigated the effects of native SS (SS-14 and/or SS-28) and
of the three octapeptide SS-analogs octreotide, BIM-23014,
and RC-160, on hormone release by cultured NFAs, prolacti-
FIG. 1. Effects of SS-28, octapeptide SS-analogs, and the DA-agonist
quinagolide on hormone release by cultures of three NFAs (nos. 1, 3,
and 6). Pituitary adenoma cells were incubated in MEM 1 10% FCS
during 72 h in quadruplicate without or with 10 nM of the drugs
indicated. Values are expressed as the percentage of hormone release
by control cells and are the mean 6 SE; *, P , 0.01 vs. control cells.
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nomas, and insulinomas to further establish whether tumors
lacking sst subtypes with high affinity for octapeptide SS-
analogs (sst2 and sst5) can be responsive to native SS. This
may give information whether sst subtypes other than sst2
and sst5 may be involved in the antihormonal actions of SS
in such tumors.
We found that, in a small subgroup of NFA cultures (3/10),
prolactinomas (3/4), and insulinomas (1/2), hormone re-
lease in vitro was insensitive or showed a very low sensitivity
to the inhibitory effects of the octapeptide SS-analogs oct-
reotide, RC-160 and BIM-23014, while at the same time hor-
mone release was inhibited by SS-14 and/or SS-28. In line
TABLE 2. The effect of long-term incubation with bromocriptine, SS-28, and octapeptide SS-analogs on hormone release by cultured
clinically nonfunctioning pituitary adenoma cells (NFA)
Culture no.
Hormone release (day 10–14 of culture)
a-SU (mU/well) FSH (mU/well) LH (mU/well)
NFA 7
Control 6.7 6 0.2 (100) 12.5 6 0.4 (100) 1.0 6 0.1 (100)
Bromocriptine (10 nM) 1.8 6 0.1 (27)a 6.7 6 0.2 (53)a 0.6 6 0.1 (60)a
SS-28 (10 nM) 2.2 6 0.2 (33)a 7.9 6 0.2 (63)a 0.8 6 0.1 (80)a
Octreotide (10 nM) 2.5 6 0.2 (37)a 8.5 6 0.4 (68)a 0.7 6 0.1 (70)a
BIM-23014 (10 nM) 1.9 6 0.3 (28)a 7.7 6 0.3 (62)a 0.7 6 0.1 (70)a
RC-160 (10 nM) 2.3 6 0.2 (34)a 8.5 6 0.3 (68)a 0.7 6 0.1 (70)a
NFA 8
Control 1.0 6 0.1 (100) 15.6 6 0.6 (100) Not detectable
Bromocriptine (10 nM) 0.3 6 0.1 (30)a 4.0 6 0.4 (26)a
SS-28 (10 nM) 1.0 6 0.1 (100) 13.7 6 1.2 (88)
Octreotide (10 nM) 0.8 6 0.1 (80) 13.8 6 1.0 (88)
NFA 9
Control 0.6 6 0.1 (100) 22.2 6 0.9 (100) Not detectable
Bromocriptine (10 nM) 0.3 6 0.0 (50)a 9.3 6 0.5 (42)a
SS-28 (10 nM) 0.6 6 0.0 (100) 16.7 6 0.5 (76)a
Octreotide (10 nM) 0.6 6 0.1 (100) 19.6 6 1.4 (90)
NFA 10
Control 3.6 6 0.2 (100) 1.8 6 0.1 (100) 0.5 6 0.0 (100)
Bromocriptine (10 nM) 1.5 6 0.1 (42)a 1.0 6 0.1 (56)a 0.4 6 0.0 (80)a
SS-28 (10 nM) 2.4 6 0.1 (67)a 1.4 6 0.1 (78)a 0.5 6 0.0 (100)
NFA 11
Control 0.4 6 0.0 (100) 7.5 6 0.1 (100) Not detectable
Bromocriptine (10 nM) 0.3 6 0.1 (75)a 3.5 6 0.1 (47)a
SS-28 (10 nM) 0.4 6 0.0 (100) 5.2 6 0.3 (69)a
Octreotide (10 nM) 0.4 6 0.0 (100) 6.5 6 0.4 (87)
The cells were cultured during 14 days without or with the test substances in Transwell tissue culture inserts as described in the Materials
and Methods section. Medium and test-substances were changed every 3–4 days. Values in brackets are the percentages of control hormone
release from days 10–14 of culture.
a P , 0.01 vs control cells. No detectable amounts of GH, PRL, and ACTH were found in the media.
FIG. 2. The effect of long-term incubation with SS-28, octapeptide SS-analogs, and the DA-agonist bromocriptine on hormone release by cultured
cells of NFA nos. 7 and 10. The pituitary adenoma cells were incubated in Transwell tissue culture inserts for 3 weeks without or with 10 nM
of the drugs indicated. Medium was changed every 3 or 4 days and stored at 220 C until determination of hormone concentrations. Values are
expressed as the percentage of hormone release of control cells at each time-point indicated and are the mean 6 SE of four wells per treatment
group. Symbols represent: (E) bromocriptine, () SS-28, (F) octreotide, () BIM-23014, (f) RC-160. The arrow at day 14 of culture indicates
the time-point of drug withdrawal.
SS(-ANALOG) EFFECTS ON ENDOCRINE TUMORS 3015
 at Medical Library Erasmus MC on December 13, 2006 jcem.endojournals.orgDownloaded from 
with the observation that the three octapeptide SS-analogs
show a comparable binding profile to the five sst subtypes,
we found no differences between the maximal inhibitory
effects of octreotide, BIM-23014, and RC-160. Comparable
results were found in GH-secreting adenomas in a previous
study (10). In this study, we also found that those adenoma
cell cultures that did not respond to octreotide did not re-
spond to BIM-23014 and RC-160 as well (10).
Octreotide, RC-160, and BIM-23014 bind with a high and
relative high affinity to sst2 and sst5, respectively, with low
affinity to sst3, and display no binding to sst1 and sst4 (1–4).
This suggests that the tumors mentioned above lack the
expression of sst2, sst5, and possibly also sst3. In a few se-
lected cases, sufficient tissue was obtained to perform both
cell culture studies and ligand binding and in situ hybrid-
ization studies. In one NFA, which showed a high density of
[125I-Tyr0]SS28 binding sites, and sst1 mRNA expression
only, hormone release was only slightly sensitive to SS-28
and not to octreotide, suggesting that activation of sst1 is not
important in mediating an antihormonal effect. However,
bLH and bFSH secretion was not measured in our study.
Previously, Klibansky et al. (12) showed that SS significantly
inhibited bLH and bFSH secretion in vitro in 53% of patients
with NFAs, whereas a-subunit secretion was inhibited in
only 17% of these tumors. Further studies are needed to
elucidate this point. Two prolactinomas that showed a low
sensitivity to SS-28 in vitro expressed sst1 and sst3 mRNA,
respectively. Prolactinoma no. 6, which responded to both
octreotide and SS-28, did not express sst2, suggesting that sst
subtypes other than sst2 are involved in the regulation of
TABLE 3. The effect of long-term incubation with bromocriptine,
SS-28, and octapeptide SS-analogs on PRL release by cultured
human prolactinoma cells
PRL release (day 10–14 of culture: ng/well)
Prolactinoma 6 Prolactinoma 7
Control 2404 6 82 4501 6 142
Bromocriptine (10 nM) 85 6 7 (4)a 1190 6 115 (26)a
SS-28 (10 nM) 1680 6 57 (70)a 3359 6 60 (75)b
Octreotide (10 nM) 1738 6 77 (72)a 3805 6 225 (85)
BIM-23014 (10 nM) Not investigated 4324 6 222 (96)
RC-160 (10 nM) Not investigated 4190 6 169 (93)
The cells were cultured during 14 days without or with the test
substances in Transwell tissue culture inserts as described in the
Materials and Methods section. Medium and test-substances were
changed every 3–4 days. Values in brackets are the percentages of
control prolactin release from days 10–14 of culture.
a P , 0.01 and b P , 0.05 vs. control cells.
TABLE 4. Effect of somatostatin and the somatostatin analogs




Control 687 6 10
SS-14 (10 nM) 490 6 9 (71)a
SS-28 (10 nM) 464 6 6 (68)a
Octreotide (10 nM) 690 6 15 (100)
RC-160 (10 nM) 672 6 22 (98)
Human insulinoma cells were incubated in quadruplicate in
MEM 1 10% FCS during 72 h with or without the compounds indi-
cated. Thereafter the media were collected and stored at 220 C until
determination of the insulin concentration by RIA. Values in brackets
are the percentages of insulin release by control cells.
a P , 0.01 vs. control cells.
FIG. 3. The effect of long-term incuba-
tion with SS, SS-analogs, and the DA-
agonist bromocriptine on PRL release
by cultured cells of prolactinomas nos. 4
and 5. The cells were cultured in Tran-
swells as described in the legend to Fig.
2. The drug concentration was 10 nM.
Values are the mean 6 SE of four wells
per treatment group and expressed as
the percentage of PRL release by con-
trol cells at each time-point. Symbols
represent: (E) bromocriptine, () SS-28,
(F) octreotide, () BIM-23014, (f) RC-
160. The arrow at day 14 of culture (cul-
ture no. 5) indicates the time-point of
drug withdrawal.
FIG. 4. The effect of long-term incubation with SS and octapeptide
SS-analogs on insulin release by cultured human insulinoma cells (no.
2). The cells were cultured in Transwells as described in Fig. 2. The
drug concentration was 10 nM. Values are the mean 6 SE of four wells
per treatment group and expressed as the percentage of insulin re-
lease by control cells at each time-point. Symbols represent: () SS-28,
(L) SS-14, (F) octreotide, () BIM-23014, (M) RC-160.
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hormone secretion in this particular case. On the other hand,
the low density of SS binding sites may also account for their
low sensitivity to SS in vitro. The insulinoma, which was
highly sensitive to the inhibitory effects of SS-28, SS-14, as
well as to the three octapeptide SS-analogs octreotide, BIM-
23014 and RC-160, did not express sst2 mRNA, suggesting
that other sst subtypes (i.e. sst5) are also important in medi-
ating the inhibition of insulin release in this case. The in-
volvement of sst3, which is also expressed in this case, cannot
be fully excluded, however. Moreover, disregulation of re-
ceptor/signaling systems, like density of receptors, desen-
sitization, signaling, or gene regulation, can be involved in
determining the response of hormone secretion to SS and SS
analogs as well.
In conclusion, sst subtypes other than sst2 and sst5 may
mediate an antihormonal effect because, in particular tumors
that were not responsive to the three octapeptide SS-analogs,
native SS was effective. Therefore, it seems reasonable to
develop sst1, sst3, and/or sst4- subtype selective SS-analogs
for the treatment of this small subgroup of patients.
Our observations seem well in agreement with the results
of studies by Greenman and Melmed (7, 19). These investi-
gators demonstrated by RNAse protection and RT-PCR as-
says the absence of sst2 mRNA in prolactinomas, whereas the
majority of the tumors expressed sst1 (4 out of 5), sst3 (3 out
of 3), and sst5 (3 out of 3) mRNA. It is also known for some
time that the vast majority of the patients with prolactinomas
do not respond to treatment with octreotide (22–23). How-
ever, data concerning sst subtype mRNA expression in pi-
tuitary adenomas are conflicting. Other groups demon-
strated sst2 mRNA expression by RT-PCR analysis in
prolactinomas in 100, 67, and 100% of the cases, respectively
(20, 21, 24). The high sensitivity of the RT-PCR technique may
be an explanation for this observation but also for the dis-
crepancy between clinical studies using octreotide in pro-
lactinoma patients on the one hand and the high incidence
of sst2 mRNA positive prolactinomas when evaluated by
RT-PCR.
In conclusion, our study demonstrates that, in a subgroup
of NFAs, prolactinomas, and insulinomas, hormone release
is inhibited by native SS, but not by the octapeptide SS-
analogs octreotide, RC-160, or BIM-23014. This suggests that,
in selected neuroendocrine tumors, sst-subtypes other than
sst2 may be involved in the inhibition of hormone release and
that novel sst-subtype specific SS-analogs might be of value
in the treatment of selected patients harboring tumors with
ssts with low affinity for octapeptide SS-analogs.
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[125I-Tyr0]-SS-28 [125I-Tyr3]-octreotide sst1 sst2 sst3
NFA no. 9 11 2 1 2 2
NFA no. 11 1 1 2 2 2
NFA no. 16 1 11 1 2 2
NFA no. 17 2 2 2 2 1
NFA no. 18 1 2 2 2 1
Prolactinoma no. 6 2 2 2 2 1
Prolactinoma no. 7 1 1 1 2 2
Insulinoma no. 2 11 11 1 2 1
Pheochromocytoma 11 11 nd 1 nd
Carcinoid 11 11 nd 1 nd
nd, Not determined. Grading: 2, negative; 1, positive; 11, strongly positive.
FIG. 5. Photomicrograph of the results of SSR-autoradiography and
of in situ hybridization of sst1, sst2, and sst3 mRNAs of insulinoma no.
2. Note the absence of sst2 mRNA. A, Hematoxylin-azophloxine
stained section; B, autoradiogram showing total binding of [125I-
Tyr0]SS-28; C, autoradiogram showing total binding of [125I-
Tyr3]octreotide; D, autoradiogram showing a high amount of sst1
mRNA; E, autoradiogram showing the absence of sst2 mRNA; F,
autoradiogram showing a high amount of sst3 mRNA. B and C, Total
binding was displaced with more than 50% by excess (1 mM) unlabeled
SS-28 or octreotide, respectively; D and F, the hybridization signal
was displaced with more than 50% by a 20-fold excess unlabeled sst1
or sst3 oligonucleotide probe, respectively; E, the very low hybridiza-
tion signal was not displaced by excess sst2 oligonucleotide probe. Bar,
1 mm.
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